Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Adaptive Research Marks Milestone Growth with First Theranostics Center in Partnership with Florida Theranostics
Thursday, December 14, 2023Adaptive Research a pioneering organization committed to democratizing clinical trials by offering comprehensive support to communitybased trial investigators today announced a landmark agreement
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
Wednesday, December 13, 2023Icosavax Inc today announced it has entered into a definitive agreement pursuant to which AstraZeneca through an acquisition subsidiary will initiate a tender offer to acquire all of Icosavaxs
Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses
Wednesday, December 13, 2023Plus Therapeutics Inc a clinicalstage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers
Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD
Tuesday, December 12, 2023Orchard Therapeutics a global gene therapy leader today announced the Swiss Agency for Therapeutic Products has approved Libmeldy a hematopoietic stem cell
SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
Tuesday, December 12, 2023SystImmune a clinicalstage biopharmaceutical company and Bristol Myers Squibb today announced an exclusive license and collaboration agreement for SystImmunes BLBD a potentially firstinclass EGFRxHER bispecific
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosis
Monday, December 11, 2023Basilea Pharmaceutica Ltd Allschwil a commercialstage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections announced today that its license partner Astellas Pharma US Inc
Effector Therapeutics Announces New Positive Interim Data From Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Er+ Metastatic Breast Cancer Patients
Saturday, December 09, 2023EFFECTOR Therapeutics Inc a leader in the development of selective translation regulator inhibitors for the treatment of cancer today announced new positive interim data from dose escalation
Kura Oncology’s Menin Inhibitor Ziftomenib Selected for the Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (Pedal) Master Clinical Trial
Saturday, December 09, 2023Kura Oncology Inc a clinicalstage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer and The Leukemia Lymphoma Society
Dantari's Novel High-Capacity Drug Conjugate DAN-222 Shows Promising Antitumor Activity in Patients with Metastatic HER2-Negative Breast Cancer
Friday, December 08, 2023Dantari Inc today announced that data from the completed doseescalation Phase clinical trial showed that DAN was safe well tolerated and demonstrated promising antitumor activity in patients with metastatic human epidermal growth
Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare Cholestatic Liver Disease, PBC
Friday, December 08, 2023Ipsen and GENFIT today announced that the US Food and Drug Administration has accepted the New Drug Application for investigational elafibranor
